Cargando…
Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma
The objective of this study is to evaluate the efficacy and safety profiles of the targeted medications, bevacizumab and cetuximab, in combination with cytostatic drugs in patients with locally advanced or metastatic pancreatic cancer. In this retrospective phase 2 study, a total of 59 patients with...
Autores principales: | Tai, Cheng-Jeng, Huang, Ming-Te, Wu, Chih-Hsiung, Wang, Chien-Kai, Tai, Chen-Jei, Chang, Chun-Chao, Hsieh, Cheng-I., Chang, Yu-Jia, Wu, Chang-Jer, Kuo, Li-Jen, Wei, Po-Lei, Chen, Ray-Jade, Chiou, Hung-Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839806/ https://www.ncbi.nlm.nih.gov/pubmed/27082562 http://dx.doi.org/10.1097/MD.0000000000003259 |
Ejemplares similares
-
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial
por: Tai, Cheng-Jeng, et al.
Publicado: (2015) -
Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016) -
Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma
por: Chen, Jianxin, et al.
Publicado: (2020) -
The outcomes of therapeutic decision in lower 3rd rectal cancer patients
por: Chen, Chien-Hsin, et al.
Publicado: (2016) -
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan
por: Hsieh, Mao-Chih, et al.
Publicado: (2017)